1. Electrochemotherapy of tumoursGregor Serša, Maja Čemažar, Damijan Miklavčič, Zvonimir Rudolf, 2006, review article Abstract: Electroehemotherapy consists of chemotherapy followed by local application of electrie pulses to the tumour to increase drug delivery into cells. Drug uptake can be inereased by electroporation for only those drugs whose transport through the plasma membrane is impeded. Among many drugs that have been tested so far, only bleomycin and cisplatin found their way from preclinical testing to clinical trials. In vitro studies demonstrated several fold inerease of their cytotoxicity after electroporation of cells. In vivo, electroporation of tumours after local or systemic administration of either ofthe drugs, i.e. electrochemotherapy, proved to be an effective antitumour treatment. In preclinical studies on several tumour models, electrochemotherapy either with bleomycin or cisplatin was elaborated and parameters for effective local tumour control were determined. In veterinary medicine, electrochemotherapy also proved to be effective in the treatment of primary tumours in cats, dogs and horses. In human clinical studies, electrochemotherapy was performed on the patients with progressive disease andaccessible tumour nodules of different malignancies. All clinical studies demonstrated that electrochemotherapy is an effective treatment for local tumour control in cancer patients.
Published in DiRROS: 15.02.2024; Views: 1215; Downloads: 202
 Full text (225,92 KB) |
2. |
3. Electrochemotherapy with cisplatin of breast cancer tumor modules in a male patientMartina Reberšek, Tanja Čufer, Zvonimir Rudolf, Gregor Serša, 2000, original scientific article Abstract: Background. The metastases of breast cancer in a male patient were treated with electrochemotherapy by intratumoral injection of cisplatin. Electrochemotherapy is chemotherapy with the subsequent local application of electric pulses to the tumor nodules in order to increase drug delivery into the cells. Case report. Cutaneous metastases of breast cancer were treated with the intratumoral administration of cisplatin and by 8 electric pulses (1300 V/cm) applied a minute later to each cutaneous metastasis. The treatmentresulted in complete response of two electrochemotherapy treated cutaneous metastases and partial response of the third metastasis. In cutaneous metastases treated with intratumoral administartion of cisplatin without electric pulses, only partial response was obtained. Conclusion. This study confirms that electrochemotherapy with cisplatin is effective in the treatment of breast cancer metastases, too, as it was already proved for electrochemotherapy with bleomycin.
Published in DiRROS: 25.01.2024; Views: 816; Downloads: 202
Full text (267,61 KB) |
4. Adenocarcinoma skin metastases treated by electrochemotherapy with cisplatin combined with radiationGregor Serša, Maja Čemažar, Zvonimir Rudolf, Albert-Peter Fras, 1999, original scientific article Abstract: Background. The aim of this study was to determine the interaction between electrochemotherapy as a means of facilitated cisplatin delivery into the cells and irradiation of adenocarcinoma skin metastases. Case report. A patient with progressive disease presenting skin metastases of tubal dedifferentiated pappilary adenocarcinoma was enrolled in the study. Skin metastases were treated by electrochemotherapy with intratumoral injection of cisplatin. Its antitumor effectiveness was compared to that of combined treatment of irradiation with electrochemotherapy. After a two week observation time, the response to treatment was comparable between the electrochemotherapy and electrochemotherapy combined with irradiation. Both ofthese treatments were more effective than irradiation alone. Furthermore, antitumor effectiveness of the combined electrochemo- and radiotherapy was found to be quicker than that of electrochemotherapy alone. Comment. This study shows that electrochemotherapy with cisplatin is also effective in the treatment of adenocarcinoma skin metastases. Inspite of the short observation time, positive interaction between radiotherapy and electrochemotherapy with cisplatin was found.
Published in DiRROS: 22.01.2024; Views: 743; Downloads: 184
Full text (410,27 KB) |
5. Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancerSimona Borštnar, Tanja Čufer, Ivan Vrhovec, Zvonimir Rudolf, 1999, original scientific article Abstract: Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2.
Published in DiRROS: 22.01.2024; Views: 972; Downloads: 208
Full text (548,70 KB) |
6. The urokinase-type plasminogen activator, its inhibitors and its receptor - the new prognostic factors in solid cancersSimona Borštnar, Tanja Čufer, Zvonimir Rudolf, 1997, review article Abstract: The urokinase-type plasminogen activator (uPA), its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR) play nan important role in the degradation of the intercellular tissue, the process which affects the ability of cancer cells to invade to surrounding tissue and to metastasize. The results of clinical studies performed in the past few years point out a significant influence of uPA, PAI-1, PAI-2 and uPAR on the course of the disease and survival of patients with solid tumours, particularly breast cancer. Hopefullythe categorization of patients according to the content of the serineproteases and its inhibitors in tumour tissues could provide a basis formore rational treatment planning and thus improving patients' survival.
Published in DiRROS: 18.01.2024; Views: 714; Downloads: 195
Full text (485,80 KB) |
7. Electrochemotherapy with bleomycin : The first clinical experience in malignant melanoma patientsZvonimir Rudolf, Borut Štabuc, Maja Čemažar, Damijan Miklavčič, Lojze Vodovnik, Gregor Serša, 1995, original scientific article Keywords: melanoma therapy, bleomycin, electric stimulation therapy
Published in DiRROS: 15.01.2024; Views: 872; Downloads: 193
Full text (418,42 KB) |
8. Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in miceMaja Čemažar, Damijan Miklavčič, Lojze Vodovnik, Tomaž Jarm, Zvonimir Rudolf, Borut Štabuc, Tanja Čufer, Gregor Serša, 1995, original scientific article Keywords: neoplasmas, experimental therapy, cisplatin, electric stimulation therapy, cell membrane permeability
Published in DiRROS: 15.01.2024; Views: 770; Downloads: 208
Full text (393,12 KB) |
9. |
10. |
